Holen Sie sich die Stockscreener-App
1.78
0.56%
-0.01
Handel nachbörslich:
1.72
-0.06
-3.37%
Dogwood Therapeutics Inc Aktie (DWTX) Neueste Nachrichten
Dogwood Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Preclinical DevelopmentEPS Growth Rate - Newser
PRODU - produ
DWTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12.00 - GuruFocus
DWTX News | DOGWOOD THERAPEUTICS INC (NASDAQ:DWTX) - ChartMill
Dogwood launches 12-week extension study for pain drug Halneuron - Investing.com UK
Dogwood launches 12-week extension study for pain drug Halneuron By Investing.com - Investing.com Australia
Chemo nerve pain patients get 12-week access to non-opioid Halneuron trial - Stock Titan
Dogwood Therapeutics, Inc. Q1 2026 SEC 10-Q Filing – Financial Statements, Management Discussion, and Risk Factors - Minichart
Dogwood Therapeutics 1Q Rev $0.00 >DWTX - Moomoo
Armistice Capital (NASDAQ: DWTX) reports 9.99% Dogwood stake - Stock Titan
Dogwood Therapeutics 1Q 2026: Revenue $2.41M, EPS ($0.15) — 10-Q Summary - TradingView
Dogwood Therapeutics (Nasdaq: DWTX) posts Q1 2026 loss, flags cash risk - Stock Titan
Dogwood Therapeutics Announces First Quarter 2026 Financial Results - Sahm
DWTX Stock Price, Quote & Chart | DOGWOOD THERAPEUTICS INC (NASDAQ:DWTX) - ChartMill
Dogwood Therapeutics 1Q Loss $4.99M >DWTX - Moomoo
Dogwood Therapeutics Reports First Quarter 2026 Results and Progress on Pain Pipeline - citybuzz -
Dogwood Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Dogwood Therapeutics Reports Q1 2026 Results, Advances Halneuron® and SP16, and Secures $100M Antiviral Partnership 1 - Minichart
Dogwood Therapeutics (NASDAQ:DWTX) Beats EPS Estimates in Q1 2026, Phase 2b Trial on Track - ChartMill
DOGWOOD THERAPEUTICS ($DWTX) Releases Q1 2026 Earnings - Quiver Quantitative
Dogwood Therapeutics reports Q1 2026 net loss $5.0M, cash $13.2M, Halneuron Phase 2b on track - TradingView
Dogwood Therapeutics (DWTX) narrows Q1 loss and advances pain pipeline - Stock Titan
Dogwood Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Dogwood Therapeutics Q1 net loss narrows, no revenue reported - TradingView
DWTX: Pipeline advances, reduced net loss, and new partnership drive positive outlook for 2026 - TradingView
Chemo pain drug developer Dogwood lands FDA, NCI backing and $100M deal - Stock Titan
Dogwood Therapeutics : Corporate Presentation (Dogwood Therapeutics Non Confidential Corporate Update May 2026) - marketscreener.com
Dogwood Therapeutics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
TradingKey - TradingKey
DWTX Dogwood stock climbs 4.2% after pharmaceutical company posts massive earnings beat, EPS smashes estimates by 94%SPAC - Newser
What separates Dogwood (DWTX) from the pack? (Eye on Rally) 2026-05-08Pre Earnings - Newser
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 - The Manila Times
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), NRX Pharmaceuticals (NRXP) and Immuneering (IMRX) - The Globe and Mail
[ARS] Dogwood Therapeutics, Inc. SEC Filing - Stock Titan
Big capital authorization vote ahead for Dogwood Therapeutics (NASDAQ: DWTX) - Stock Titan
Dogwood Therapeutics files to sell 28.04M shares of common stock for holders - MSN
Dogwood licenses IMC-1, IMC-2 antiviral assets to PRIDCor By Investing.com - Investing.com Canada
Dogwood licenses IMC-1, IMC-2 antiviral assets to PRIDCor - Investing.com
Dogwood Therapeutics Announces Worldwide Development and - GlobeNewswire
DWTX (Dogwood Therapeutics Inc.) posts far narrower Q4 2025 loss than consensus estimates, yet shares dip 4.47% today.Momentum Score - Cổng thông tin điện tử Tỉnh Sơn La
Dogwood Therapeutics, Inc. (DWTX) Advances SP16 Program with FDA Investigational New Drug Approval - Insider Monkey
5 Oversold Biotech Stocks to Invest In Now - Insider Monkey
Dogwood Therapeutics (DWTX) seeks approval to increase authorized shares to 195M - Stock Titan
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy - Sahm
Dogwood Therapeutics receives FDA clearance for SP16 pain trial By Investing.com - Investing.com Australia
Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Large Increase in Short Interest - MarketBeat
Dogwood Therapeutics receives FDA clearance for SP16 pain trial - Investing.com
Dogwood Therapeutics Announces FDA Acceptance of SP16 - GlobeNewswire
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):